416 DOSE TITRATION FOR SUPERSTIMULATION OF BRANGUS AND BONSMARA DONORS WITH Folltropin®-V BY A SINGLE INTRAMUSCULAR INJECTIOND. Rogan C , A. Tríbulo A , H. Tríbulo A , R. Tríbulo A , D. Carballo Guerrero A , P. Tríbulo A , R. J. Mapletoft D and G. A. Bó A
A Instituto de Reproducción Animal Córdoba, Zona Rural, Gral Paz, Córdoba, Argentina;
B Universidad Nacional de Córdoba, Córdoba, Argentina;
C Bioniche Life Sciences, Belleville, Ontario, Canada;
D Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Reproduction, Fertility and Development 22(1) 365-365 https://doi.org/10.1071/RDv22n1Ab416
Published: 8 December 2009
Two experiments were designed to evaluate the superovulatory response of Brangus and Bonsmara donor cows to different dosages of Folltropin®-V (Bioniche Animal Health Inc., Belleville, Ontario, Canada) given by a single i.m. injection or twice-daily i.m. injections. In Experiment 1, Brangus cows (n = 12) were superstimulated by 6 treatments (2 × 3 factorial) in a crossover design (i.e. all cows received the 6 treatments and all treatments were represented on each day). On Day 0, cows received 5 mg of estradiol-17β plus 50 mg of progesterone and a Cue-Mate® (Bioniche Animal Health Inc.). On Day 4, cows were superstimulated with 300, 260, or 200 mg of NIH-FSH-P1 Folltropin®-V (Bioniche Animal Health Inc.) in twice-daily decreasing doses over 4 days or diluted in a slow release formulation (SRF; Bioniche Animal Health) and given in a single i.m. injection. The single injection was prepared by diluting the Folltropin®-V lyophilized powder in 1 mL of saline followed by mixing with 9 mL of the SRF in the syringe immediately before administration. In the am and pm of Day 6, all cows received PGF2, and Cue-Mates® were removed in the pm. Cows received 12.5 mg of porcine LH (Lutropin®-V; Bioniche Animal Health Inc.) in the am of Day 8 and were inseminated 12 and 24 h later. Ova/embryos were collected on Day 15 and data were analyzed by ANOVA. There was no effect of treatment (i.e. single v. twice-daily injections; P > 0.2) nor a treatment by dosage interaction (P < 0.6) on the mean (± SEM) number of total ova/embryos or transferable embryos (13.1 ± 1.9 and 7.5 ± 1.2 v. 15.5 ± 1.7 and 7.6 ± 1.0 for single v. twice-daily injections, respectively). The total number of ova/embryos did not differ among Folltropin®-V dosages (15.0 ± 2.3, 15.7 ± 2.0, and 12.1 ± 2.5 for 300, 260, and 200 mg, respectively; P > 0.4). However, the number of transferable embryos tended (P < 0.09) to be higher in donors receiving 260 mg (9.5 ± 1.6) than 200 mg (5.2 ± 0.8), with 300 mg (7.9 ± 1.5) intermediate. In Experiment 2, Bonsmara cows (n = 16) were superstimulated by 4 treatments (2 × 2 factorial) in a crossover design similarly to Experiment 1, except that 2 dosages of Folltropin®-V (200 and 300 mg) were evaluated. There were no significant effects of dosage of Folltropin®-V (P > 0.9), treatment (P > 0.3), or interaction (P < 0.4) on embryo production. The total number of ova/embryos and transferable embryos were 11.9 ± 2.0 and 7.2 ± 1.1 v. 11.1 ± 1.1 and 7.6 ± 0.7 for single and twice-daily injections, respectively, and 11.9 ± 1.9 and 7.6 ± 1.0 v. 11.1 ± 1.3 and 7.2 ± 0.8 for 300 and 200 mg of Folltropin®-V, respectively. Superstimulation of Brangus and Bonsmara cows with a single i.m. injection of Folltropin®-V diluted in a SRF resulted in comparable embryo production to twice-daily administration of Folltropin®-V over 4 days. While 260 mg seems to be the most appropriate dosage for Brangus donors, 200 mg seems to be adequate for Bonsmara donors.